EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Disease and economic burden of surgery in desmoid tumors: a review

Maria M Fernandez, Timothy Bell, Brad Tumminello, Shahnaz Khan, Shengfan Zhou, Ana B Oton

Expert Review of Pharmacoeconomics & Outcomes Research · 2023

DOI: 10.1080/14737167.2023.2203915 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2023. Verfasst von Maria M Fernandez und 5 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, NC, USA. Hauptthemen laut MEDLINE: Desmoid Tumors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SpringWorks Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Desmoid tumors (DT) are soft-tissue tumors that infiltrate into surrounding structures with ill-defined margins. Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function. AREAS COVERED: We conducted a literature review to assess the burden of surgery in patients with DT, focusing on recurrence rates and functional deficits resulting from surgeries. Since economic data related to DT surgery is lacking, reviews of surgery costs in soft-tissue sarcomas and of general costs of amputations were conducted. Risk factors for DT recurrence after surgery are young age ( 5 cm in greatest diameter), positive resection margins, and history of trauma in the area of the primary tumor. Tumors in the extremities have the highest risk of recurrence (30%-90%). Lower rates of recurrences have been reported when radiotherapy was used after surgery (14%-38%). EXPERT OPINION: Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs. Therefore, it is imperative to find alternative treatments with acceptable efficacy and safety profiles that do not adversely affect functional aspects in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desmoid TumorsHumansAdultFinancial StressNeoplasm Recurrence, LocalRisk FactorsRetrospective Studies

Stichwörter der Autor:innen

Aggressive fibromatosiscostsdesmoid tumorsfunctional outcomesquality of liferecurrence ratesurgerysystemic therapy

Autor:innen und Institutionen

  • RTI Health Solutions, Research Triangle Park, NC, USA.
  • Medical Affairs, SpringWorks Therapeutics, Inc., Stamford, CT, USA.

Förderung

  • SpringWorks Therapeutics

Zitieren

APA

Fernandez, M. M., Bell, T., Tumminello, B., Khan, S., Zhou, S., & Oton, A. B. (2023). Disease and economic burden of surgery in desmoid tumors: a review. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2203915

Vancouver

Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Review of Pharmacoeconomics & Outcomes Research. 2023. doi:10.1080/14737167.2023.2203915

BibTeX
@article{Fernandez2023,
  author = {Fernandez, Maria M and Bell, Timothy and Tumminello, Brad and Khan, Shahnaz and Zhou, Shengfan and Oton, Ana B},
  title = {Disease and economic burden of surgery in desmoid tumors: a review},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2023},
  doi = {10.1080/14737167.2023.2203915}
}
Kostenlos starten →